05/30/23 8:00 AMNasdaq : BOLT BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseasesBioLight is proud to report it has signed a research collaboration agreement with Alexion, focusing on exploring a groundbreaking technology that utilizes natural tears for the potential diagnosis of retinal diseases. The study, financed by Alexion and BioLight, will evaluate a screening technique that analyzes...RHEA-AIneutral
05/25/23 5:05 PMNasdaq : BOLT clinical trialBolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual MeetingTreatment with BDC-1001 at the recommended Phase 2 dose (RP2D) resulted in 29% objective response rate in evaluable patients with HER2-positive tumors, in both monotherapy and in combination with nivolumab 20 mg/kg dosed every other week (q2w) was selected as the RP2D BDC-1001 advancing to aRHEA-AIpositive
05/11/23 4:05 PMNasdaq : BOLT earningsBolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateComprehensive BDC-1001 clinical safety and efficacy data as a single agent and in combination with nivolumab, including RP2D, to be presented at ASCO 2023 BDC-1001 Phase 2 program expected to initiate in 2023 in HER2+ colorectal, endometrial, gastroesophageal, and breast cancer Cash balance ofRHEA-AIneutral
04/26/23 10:00 AMNasdaq : BOLT conferencesclinical trialBolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual MeetingBolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer,RHEA-AIneutral
03/29/23 4:15 PMNasdaq : BOLT earningsBolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatePositive topline data from BDC-1001 dose-escalation clinical study validates the ability of the Boltbody™ ISAC platform to generate anti-tumor activity with acceptable safety BDC-1001 advances into a focused Phase 2 program commencing in 2023: a trial as monotherapy and in combination withRHEA-AIpositive
03/29/23 4:05 PMNasdaq : BOLT clinical trialBolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical StudiesBDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with nivolumab Data support selection of a recommended Phase 2 dose and advancement into Phase 2 studies in breast,RHEA-AIpositive
03/14/23 4:30 PMNasdaq : BOLT conferencesclinical trialBolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual MeetingBolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that it will present a poster with new preclinical data for BDC-3042,RHEA-AIvery positive
02/28/23 8:00 AMNasdaq : BOLT conferencesBolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare ConferenceBolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will present a company overview at the Cowen 43rdRHEA-AIneutral
02/01/23 8:00 AMNasdaq : BOLT conferencesBolt Biotherapeutics to Present at February Investor ConferencesBolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in two upcoming conferences inRHEA-AIneutral
12/14/22 4:43 PMNasdaq : BOLT managementBolt Biotherapeutics Appoints Laura Berner to Board of DirectorsBolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14,RHEA-AIpositive